MTOR and lymphangioleiomyomatosis: Adding that only 50% of human mesenchymal tumors, and 31% of Tsc2+/− mouse renal tumors exhibit altered mTOR pathway activation, supports the existence of tumorigenic mTOR-independent mechanisms causing LAM pathogenesis [146].